0:00
The talk is about drug
metabolism in liver disease.
I am an associate professor
in pharmacology and toxicology
at the American
University of Beirut.
Please feel free to email
me if you have any question.
0:14
I'd like to acknowledge
Dr. Robert Branch
from the University of Pittsburgh.
He's my mentor.
A lot of the studies
that I will mention today
were conducted by his group.
He has given the
original talk in 2007.
0:29
Here's the outline
that I will follow.
I will first start with a
little bit of background
on drug metabolism in liver disease.
Is there any evidence of change?
And is this clinically relevant?
This is very important
for physicians
who prescribe those drugs in
the setting of liver disease.
Then, we will talk
about pathophysiology
of liver disease and physiology
of hepatic elimination.
And with this
background, then you will
be able to understand
better the effect of
liver disease on drug metabolism.
We will talk about the
intact hepatocyte theory.
And then move on to the progressive,
sequential model in liver disease.
And after that, we will see
some applications of this model
in liver disease over
time and whether it
has a role in disease prognosis.
We will look at different
disease entities,
such as cholestatic liver disease
versus non-cholestatic
liver disease.
And towards the end, we will
try to see if gene expression
or epigenetic mechanisms such as
DNA methylation and miRNA expression
can be used as biomarkers of
drug metabolism in liver disease.
1:38
We all know that drug
metabolizing enzymes
are concentrated in the liver.
Hence, it would make sense that
most probably liver disease affects
their expression and activity.
